Kamada stock: Kamada announced two November conferences for Kamada stock

Published on 10/22/2026 at 04:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kamada's CEO will present in New York on November 10, 2026. Kamada stock appears in a second London conference on November 16, 2026.

Growth dates and portfolio scale

Kamada announced two investor conferences on October 19, 2026.
Two biosimilar launches support a 150.00 percent stated sales increase from 2026 to 2028.
Kamada's market capitalization was USD 448.9 million as of October 21, 2026.

KMDA, IL0010941198, Illustration mit AI erstellt.

Kamada Ltd. (ISIN IL0010941198) announced two investor conferences in November 2026, including a presentation on November 10, 2026, according to GlobeNewswire on October 19, 2026. Chief Executive Officer Amir London is scheduled to present at the Stifel Healthcare Conference in New York, while Kamada will also participate in the Jefferies Global Healthcare Conference in London.

Three events shape the picture

Kamada's recent disclosures show a company combining commercial expansion with tighter reporting practices. On October 5, 2026, Kamada said it would improve future disclosures on inventory accounting for fiscal years 2024 and 2025, as reported in its Form 6-K summary by StockTitan. On October 6, 2026, the company launched two biosimilars in Israel, lifting its marketed biosimilar portfolio to four, according to Yahoo Finance. The October 19 conference announcement is the latest of the three events.

What can biosimilars add?

The financial significance is concentrated in the stated sales path. Kamada expects its existing commercial biosimilar portfolio to generate USD 4.00 million in sales in 2026 and USD 10.00 million in 2028, a 150.00 percent increase across that period, according to the October 6 release. The company also expects at least two additional products in 2027 and a portfolio of at least 12 marketed products by 2030. That plan gives the November presentations a specific operating topic: whether broader distribution and licensing can turn a four-product base into a larger recurring contributor.

Which dates matter next?

The next disclosed investor date is November 10, 2026, when London is scheduled to present at the Stifel Healthcare Conference. The second conference is scheduled for November 16, 2026, at the Jefferies Global Healthcare Conference in London, according to GlobeNewswire. These dates can provide updated detail on product launches, plasma collection and the licensing pipeline.

Market value stays measurable

Kamada's market capitalization was USD 448.9 million as of October 21, 2026. Its 52-week range was USD 6.55 to USD 9.35 on the same date, giving investors a defined valuation frame while the company develops its biosimilar portfolio.